STI-6129
As of the edition of 20 October 2026, STI-6129 is a drug known only by a code name: in active development; acts on CD38.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2025
- Kind
- Code name only
- Registered trials
- 5, 1 stopped early
- Disease areas
- Blood and lymph; Cancer; Heart and blood vessels; Immune system; Nutrition and metabolism
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| CD38 | ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 | P28907 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 2 | 0 | 0 | 1 |
| Phase 2 | 3 | 0 | 1 | 0 |
| All trials | 5 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Sorrento Therapeutics | Lead sponsor of trials | 2021 to now |
| Zhejiang ACEA Pharmaceutical | Lead sponsor of trials | 2023 to now |